

PANCREATIC NEUROENDOCRINE

ALLIANCE-A022001-PNETS Lutetium LU 177 Dotatate PRRT vs Capecitabine and Temozolomide in PNET

This is a phase II randomized, prospective trial of Lutetium LU 177 Dotatate PRRT versus Capecitabine and Temozolomide in well-differentiated pancreatic neuroendocrine tumors.

[NCT05247905](https://clinicaltrials.gov/ct2/show/study/NCT05247905)

Histologic or pathologic documentation of well-differentiated pancreatic neuroendocrine tumor (G1, G2, or well-differentiated G3) confirmed by local histology and/or pathology. Functional or nonfunctional tumors are allowed.
